Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.58 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30788019 | 0.86 | SLC6A2 (0.68) | OPRD1OPRM1SLC6A2CALCRL | |
| SCHEMBL31596917 | 0.86 | SLC6A2 (0.71) | OPRD1OPRM1SLC6A2CALCRL | |
| SCHEMBL29398783 | 0.85 | OPRM1 (0.57) | OPRD1OPRM1SLC6A2CALCRL | |
| SCHEMBL30788025 | 0.85 | CALCRL (0.61) | SLC6A2CALCRL | |
| SCHEMBL30439765 | 0.83 | SLC6A2 (0.56) | OPRD1OPRM1SLC6A2CALCRL | |
| SCHEMBL31720929 | 0.83 | SLC6A2 (0.56) | OPRD1OPRM1SLC6A2CALCRL | |
| SCHEMBL30289679 | 0.83 | SLC6A2 (0.58) | OPRD1OPRM1SLC6A2CALCRL | |
| SCHEMBL30407795 | 0.83 | NMUR2 (0.54) | OPRD1OPRM1 | |
| SCHEMBL30788014 | 0.82 | CALCRL (0.60) | SLC6A2CALCRL | |
| SCHEMBL30102155 | 0.82 | OPRD1 (0.55) | OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406911-A1 | COMPOSITIONS AND METHODS FOR PREVENTING, INHIBITING, DISRUPTING, OR TREATING A POLYMICROBIAL BIOFILM | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2023-12-21 | — | — | US | claimed |
| EP-4237445-A2 | COMPOSITIONS AND METHODS FOR PREVENTING, INHIBITING, DISRUPTING, OR TREATING A POLYMICROBIAL BIOFILM | Research Institute at Nationwide Children's Hospital (US) | 2023-09-06 | — | — | EP | claimed |
| CN-116490778-A | Compositions and methods for preventing, inhibiting, disrupting or treating a multi-microbial biofilm | 国家儿童医院研究所 | 2023-07-25 | — | — | CN | claimed |
| CN-114796444-A | Active composition for relieving chronic alcoholic liver injury and preparation method and application thereof | 上海朗泰凯尔生物技术有限公司 | 2022-07-29 | — | — | CN | claimed |
| WO-2022094433-A2 | COMPOSITIONS AND METHODS FOR PREVENTING, INHIBITING, DISRUPTING, OR TREATING A POLYMICROBIAL BIOFILM | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2022-05-05 | — | — | WO | claimed |
| US-12595288-B2 | Vasopressin-2 receptor antagonist peptides and uses thereof | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2026-04-07 | — | — | US | disclosed |
| US-12577291-B2 | Means and methods for treating and diagnosing fibrosis or fibrosis-associated diseases | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2026-03-17 | — | — | US | disclosed |
| US-12410229-B2 | PTH mimetic peptide based on protein domain reconstruction and application thereof | YANG DEHONG (CN) | 2025-09-09 | — | — | US | disclosed |
| US-20250258166-A1 | MEANS AND METHODS FOR HIGH-THROUGHPUT GLYCOPROFILING OF PROTEINS | GLYCANOSTICS S.R.O. (SK) | 2025-08-14 | — | — | US | disclosed |
| EP-2742058-B1 | ANTI-IL-6 VACCINE COMPOSITION | PEPTINOV (FR) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025096668-A1 | SYSTEM AND COMPOSITIONS COMPRISING MHC SCAFFOLD AND METHODS OF IDENTIFYING ANTIGENS USING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-119930842-A | Means and methods for treating angiogenesis, fibrosis and cancer related diseases with protein oligomers comprising NC-1-Fc | 海德堡生物技术有限公司 | 2025-05-06 | — | — | CN | disclosed |
| EP-4096697-A1 | PEPTIDES USEFUL IN PRESERVATION AND/OR RESTORATION OF FUNCTIONAL PANCREATIC ISLETS AND IN TREATING DIABETES | The National Institute for Biotechnology in the Negev Ltd. (IL) | 2022-12-07 | — | — | EP | disclosed |
| WO-2022248615-A2 | HEXOKINASE-DERIVED PEPTIDES AND THERAPEUTICAL USES THEREOF | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-12-01 | — | — | WO | disclosed |
| CN-111825760-B | Polypeptide and application thereof in resisting glomerular basement membrane disease | 北京大学第一医院 | 2022-11-11 | — | — | CN | disclosed |
| CN-114796444-A | Active composition for relieving chronic alcoholic liver injury and preparation method and application thereof | 上海朗泰凯尔生物技术有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2022094433-A2 | COMPOSITIONS AND METHODS FOR PREVENTING, INHIBITING, DISRUPTING, OR TREATING A POLYMICROBIAL BIOFILM | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022087519-A1 | SURFACE MODIFIED SCAFFOLDS AND METHODS OF USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-108350046-B | Analogs of VDAC 1-derived peptides | 在本-古里安大学的B．G．内盖夫科技与应用有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20220054584-A1 | ANTIMICROBIAL FUSION PEPTIDES | THE LUNDQUIST INST FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL CENTER (US) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595288-B2 | Vasopressin-2 receptor antagonist peptides and uses thereof | AVPR2, AVPR1A, AVPR1B | OPRD1 160/4885OPRM1 206/4885SLC6A2 292/4885 |
| US-12577291-B2 | Means and methods for treating and diagnosing fibrosis or fibrosis-associated diseases | MMP1, FN1, COL14A1 | OPRD1 4047/4885OPRM1 3787/4885SLC6A2 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.